Exciting possibilities emerge for Parkinson's Disease treatment as a former trial drug, initially used for diabetes, shows promise in improving motor symptoms linked to the disease. The lack of disease modifying therapeutics for Parkinson's creates an urgent need for innovative approaches, particularly to address the aggregation of alpha-synuclein and its detrimental effects on cellular health. Additionally, the discovery of a connection between early hallucinations and rapid cognitive decline highlights the importance of early detection and intervention as markers for severe Parkinson's Disease. Furthermore, researchers have identified a highly-expressed protein that aids in removing damaged mitochondria, opening doors to potential new treatments for Parkinson's and other diseases stemming from mitochondrial breakdown.
Following are some of the interesting articles:
1)
A former trial drug raises hope by 2030
Research suggests that a former drug used in trial of diabetes could be used for treating Parkinson’s Disease. A drug designed for treating Dyskinesia, a common symptom that is a side effect in PD patients taking specific medications for years, can also improve motor symptoms linked to PD. These findings raise hope of getting a multi-faceted treatment for the disease by 2030.
Following is the linked to the original source:
2)
Disease modifying therapeutics needed
Currently, there is no disease modifying therapeutics available for Parkinson’s Disease. While there have been a lot of efforts in managing the symptoms, alpha-synuclein remains untreated there by leaving it to get aggregated causing cellular toxicity and disease progression. There is clearly a need to develop novel approach to eliminate alpha synuclein aggregates.
Following is the link to the original source:
3)
Early hallucinations may lead to faster cognitive decline
Researchers have been able to link minor hallucinations to more rapid deterioration of frontal executive functioning in subsequent years. Hence, there is clearly a need of early detection and intervention as marker for severe Parkinson’s Disease. Hallucinations during early stages of Parkinson’s Disease may be a warning for rapid cognitive decline. Early hallucinations is found in 1/3rd patients prior to onset of motor symptoms.
Following is the link to the original source:
4)
A protein to the rescue
Researchers have found that a highly-expressed protein can help the body remove damaged mitochondria. This could lead to a potentially new treatments for Parkinson’s Disease. Mitochondria are tiny structures found in cells that are essential for proper body functioning. Breaking down of mitochondria can lead to range of diseases.
Following is the link to the original source:
Comments